Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study.

Molecular oncology·2026

Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026

Same author

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Science translational medicine·2026

Same author

Functional dysconnectivity in breast cancer patients undergoing hormone therapy.

Journal of clinical and experimental neuropsychology·2026

Same author

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I.

The Journal of clinical investigation·2025

Same author

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026

Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026

Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026

Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026

Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026

Same journal

Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.

The oncologist·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 28, 2026

A Method for Lineage Tracing of Corneal Cells Using Multi-color Fluorescent Reporter Mice

A Method for Lineage Tracing of Corneal Cells Using Multi-color Fluorescent Reporter Mice

Published on: December 18, 2015

Tamoxifen--what next?

William J Gradishar¹

¹Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St. Clair, Suite 850, Chicago, Illinois 60611, USA. w-gradishar@northwestern.edu

|July 22, 2004

Summary

This summary is machine-generated.

Newer endocrine therapies, including aromatase inhibitors and fulvestrant, offer improved efficacy and tolerability over tamoxifen for advanced breast cancer (ABC). Sequential use of these agents may extend treatment options and avoid chemotherapy toxicity.

More Related Videos

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Published on: January 20, 2014

A Practical Approach to Genetic Inducible Fate Mapping: A Visual Guide to Mark and Track Cells In Vivo

A Practical Approach to Genetic Inducible Fate Mapping: A Visual Guide to Mark and Track Cells In Vivo

Published on: December 30, 2009

Related Experiment Videos

Last Updated: Jan 28, 2026

A Method for Lineage Tracing of Corneal Cells Using Multi-color Fluorescent Reporter Mice

A Method for Lineage Tracing of Corneal Cells Using Multi-color Fluorescent Reporter Mice

Published on: December 18, 2015

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration

Published on: January 20, 2014

A Practical Approach to Genetic Inducible Fate Mapping: A Visual Guide to Mark and Track Cells In Vivo

A Practical Approach to Genetic Inducible Fate Mapping: A Visual Guide to Mark and Track Cells In Vivo

Published on: December 30, 2009

Area of Science:

Oncology
Endocrinology

Background:

Advanced breast cancer (ABC) management focuses on palliative care due to disease progression.
Endocrine therapy offers efficacy with minimal toxicity, making tolerability crucial for ABC patients.

Purpose of the Study:

To review the efficacy and tolerability of newer endocrine agents compared to tamoxifen in advanced breast cancer.
To discuss the role of sequential endocrine therapy in managing advanced breast cancer.

Main Methods:

Review of evidence comparing aromatase inhibitors (anastrozole, letrozole, exemestane) and fulvestrant with tamoxifen.
Analysis of studies on sequential use of endocrine agents in advanced breast cancer.

Main Results:

Aromatase inhibitors demonstrate superior efficacy and tolerability to tamoxifen in first-line treatment of postmenopausal, hormone-sensitive ABC.
Fulvestrant is effective and well-tolerated after tamoxifen failure, with no cross-resistance.
Sequential endocrine therapy is a viable, active, and well-tolerated option for advanced breast cancer.

Conclusions:

Newer endocrine agents represent advancements over tamoxifen for advanced breast cancer.
Optimizing sequences of endocrine therapies is key to future management of advanced breast cancer.
Endocrine therapy remains a vital, less toxic option for advanced breast cancer patients.